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Background: Cancerous cells are known to metastasize to different ocular structures. This happens especially to the
choroid in males with lung cancer and females with breast cancer. However, we observed two cases of cancerous
metastasis to the optic canal region. Both cases showed only a progressive decrease in vision without any other
remarkable ophthalmological symptoms or abnormalities in the affected eye.
Case presentation: Two females, a 60-year-old and a 73-year-old, came to our hospital because of progressive loss
of vision. These patients showed no remarkable symptoms or signs in their eyes except visual acuity loss. Several
ophthalmoscopic examinations, such as slit lamp microscopy and fundoscopy, showed no abnormal changes in
their affected eye but magnetic resonance imaging indicated a massive legion around the optic nerve.
Conclusion: It is possible for cancer to metastasize to the optic canal region and the existence of primary tumors
should be considered.
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Primary and secondary orbital tumors, including intraorbi-
tal and optic nerve tumors, are uncommon observations in
daily medical practice. The primary orbital tumors are soli-
tary fibrous tumors, rhabdomyosarcomas, meningiomas,
gliomas and others. Secondary orbital tumors include post-
transplantation lymphoproliferative disorders and meta-
static rhabdomyosarcomas [1]. Primary optic nerve tumors
include meningiomas, gliomas and malignant melanomas,
and secondary optic nerve tumors include metastases from
breast cancer, leukemia, retinoblastoma and gliomatosis
cerebri. An earlier study reported that optic nerve tumors
make up 8% of all orbital tumors [2] and metastases to the
optic nerve area are rare [2-4].Case presentations
Case 1: A 60-year-old woman came to our hospital after
experiencing a progressive decrease in vision in her left
eye of several months duration. Her medical history was* Correspondence: tamapiro@pk9.so-net.ne.jp
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reproduction in any medium, provided the ornot significant except for having diabetes mellitus. The
cause of the progressive decrease in vision could not be
determined. At her first visit to our hospital, the visual
acuity in her right eye was 6/6 but the vision in her left
eye had decreased to <6/60. We performed a visual field
test and confirmed the visual field loss in her left eye.
All ophthalmological tests were normal; e.g., a slit lamp
examination did not indicate cornea, pupil or lens abnor-
malities and a fundoscopic examination, and fluorescent
fundus angiography showed no remarkable changes such
as optic atrophy or retinal ischemic changes. However,
magnetic resonance imaging (MRI) showed a massive le-
sion in the optic nerve area (Figure 1A–C). Therefore, we
suspected a primary orbital tumor and performed a neuro-
surgical examination. During the neurosurgery to remove
the tumor, the mass was seen to surround the optic nerve.
The tumor was removed with only aspiration and samples
were submitted for histopathological examination. Sections
of the aspirated tissue showed that it was a ductal carcin-
oma (Figure 1D) and immunohistochemical staining of this
carcinoma was positive for cytokeratin, an epithelial cell
marker for the estrogen receptor, and for GCDFP-15, an
apocrine cell marker (Figure 1E–G). These morphological
features were compatible with metastasis from a breast car-
cinoma. We performed positron emission tomography–td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Magnetic resonance image and pathological examination of a patient with breast cancer that metastasized to the left optic
nerve region. A–C: Tumor mass (white circle) is seen conflicted in the optic canal, surrounding the optic nerve. D–G: Histopathological examination
of biopsied tissue stained with hematoxylin-eosin (HE) and immunohistochemical staining (original magnification × 200). D: Infiltrating ductal carcinoma
arranged in cords, cluster and trabeculae (HE staining). E: Cytokeratin staining as an epithelial cell marker. F: Estrogen receptor staining. G: GCDFP-15
staining as an apocrine cell marker.
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sions throughout the body and confirmed the existence of
breast cancer in the left mamma with multiple bone metas-
tases. Seven months after the surgery, her visual field had
recovered, although central scotoma had remaind. Thus
her visual acuity had not recovered from 6/60.
Case 2: A 73-year-old female noted a decrease in the
visual acuity of her right eye for a month. She had no
remarkable medical history that could cause such a pro-
gressive decrease in vision. Her visual acuity in the right
eye was counting fingers, and there was a central scot-
oma in her right visual field with no abnormal changes
observed with a slit lamp examination and fundoscopic
examination. Her left eye was completely normal. Weconsidered the existence of an orbital tumor and exam-
ined her with MRI. MRI showed one mass restricted to
the optic nerve region and another mass located be-
tween the occipital lobes (Figure 2A). Her left visual
field was normal and there was no homonymous hemi-
anopsia. We therefore thought the main cause of her visual
loss was the mass at the optic nerve region, and we next
performed a surgical biopsy. Histopathological examination
of the biopsied tissue showed that it was a metastatic
adenocarcinoma (Figure 2B), and immunohistochemical
staining showed that it was positive for thyroid transcrip-
tion factor 1 (TTF-1), which is a marker for lung adenocar-
cinoma (Figure 2C). During the surgery, the tumor was
found to surround the optic nerve, and the upper wall of
Figure 2 Magnetic resonance image and histopathological examination of Patient 2 showing breast cancer metastasis to the left optic
nerve region. A: MRI shows one tumor mass in the optic canal surrounding the optic nerve (white circle) and another mass between the
occipital lobes (white triangle). B–C: Pathological examination of metastasized cancer tissue stained with HE and immunohistochemical staining
(original magnification × 200). B: Infiltrating adenocarcinoma arranged in irregular-shaped glands (HE staining). C: Thyroid transcription factor 1
(TTF-1), the marker of lung adenocarcinoma.
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growth. We also performed PET-CT body scans for cancer
screening and confirmed that the primary lesion was in her
right lung with multiple bone metastases. Six months after
the surgery, her visual acuity recovered to 6/60.
Conclusion
Both of our cases were secondary tumors as a result of
metastases from either a primary breast cancer or lung
cancer. We suggest that the growth of the tumor in the
optic canal exerted pressure on the optic nerve, which
led to the progressive decrease in vision. This was sup-
ported by the stationary state and recovery of visual
field or visual acuity after surgical removal of the meta-
static tumor. Thus, we concluded that the tumor in
both patients was secondary and the immunohisto-
chemical staining suggested that the primary cancer was
in the breast in Patient 1 and in the lung in Patient 2.
PET-CT body scans confirmed the immunohistochemi-
cal findings.
We presented our findings on two patients whose only
sign and symptom was a progressive decrease in vision.
Histopathological examinations of the excised tissues
suggested that the retrobulbar tumors were metastases
from breast cancer in one patient and lung cancer in the
other patient. PET-CT body scans confirmed not only
the location of the primary cancer but also the locationof the metastatic area. Thus, our examinations of these
two patients led not only to stopping the loss of vision
but also determining the location of the life-threatening
cancer.
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